Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 known ✓ | P22001 | 1/20 | 0.43 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.43 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.43 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.43 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.43 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.43 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.43 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.43 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.41 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.41 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8381 | 0.99 | ALDH1A1 (0.57) | ALDH1A1MAPTHSD17B10TSHRCASP7 | |
| Hydrochloric Acid SCHEMBL8983 | 0.90 | ALDH1A1 (0.46) | ALDH1A1MAPTHSD17B10TSHRKDM4E | |
| SCHEMBL9656 | 0.89 | GABRP (0.46) | ALDH1A1MAPTHSD17B10TSHRKDM4E | |
| Hydrochloric Acid SCHEMBL9032 | 0.86 | NPC1 (0.55) | ALDH1A1MAPTHSD17B10TSHRKDM4E | |
| SCHEMBL8254 | 0.85 | NPC1 (0.56) | ALDH1A1MAPTHSD17B10TSHRKDM4E | |
| Hydrochloric Acid SCHEMBL29651829 | 0.79 | NPC1 (0.55) | ALDH1A1MAPTHSD17B10TSHRKDM4E | |
| Hydrochloric Acid SCHEMBL9337 | 0.79 | NPC1 (0.55) | ALDH1A1MAPTHSD17B10TSHRKDM4E | |
| SCHEMBL8257 | 0.79 | GABRP (0.52) | MAPTTSHRKDM4EGABRPGABRD | |
| SCHEMBL8459 | 0.78 | GABRP (0.51) | MAPTTSHRKDM4EGABRPGABRD | |
| SCHEMBL8599 | 0.78 | GABRP (0.51) | MAPTTSHRNPC1RAB9AGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | claimed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | claimed |
| EP-4292596-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | Curon Biopharmaceutical (Shanghai) Co., Limited (CN) | 2023-12-20 | — | — | EP | claimed |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | claimed |
| EP-3050876-A2 | KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-08-03 | — | — | EP | claimed |
| EP-2496567-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2012-09-12 | — | — | EP | claimed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | claimed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | claimed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-20240139198-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) | 2024-05-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| EP-4292596-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | Curon Biopharmaceutical (Shanghai) Co., Limited (CN) | 2023-12-20 | — | — | EP | disclosed |
| EP-2916868-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS S A (CH) | 2022-05-11 | — | — | EP | disclosed |
| US-11065236-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | RHIZEN PHARMACEUTICALS SA (CH) | 2021-07-20 | — | — | US | disclosed |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| EP-2496567-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | KCNA3 4163/4885GABRP 1342/4885GABRD 2739/4885 |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | KCNA3 4163/4885GABRP 1342/4885GABRD 2739/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | KCNA3 4163/4885GABRP 1342/4885GABRD 2739/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | KCNA3 4163/4885GABRP 1342/4885GABRD 2739/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | KCNA3 3782/4885GABRP 2530/4885GABRD 4049/4885 |
| US-11065236-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | PIK3CD, PIK3R4, PIK3CG | KCNA3 3354/4885GABRP 930/4885GABRD 2870/4885 |
| US-20240139198-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | PDCD1, PDCD1LG2, CD274 | KCNA3 4747/4885GABRP 998/4885GABRD 1790/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | KCNA3 4163/4885GABRP 1342/4885GABRD 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.